Status:
UNKNOWN
The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)
Lead Sponsor:
Centre Leon Berard
Conditions:
Pancreas Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this trial is to evaluate the correlation between the intensity of the protein big-h3 expression at tumoural microenvironment and the TNM/UICC staging (from I to IV) of pancre...
Detailed Description
The pancreatic adenocarcinoma is the most common pancreatic cancer. Currently, it represents the fourth cause of death by cancer in France. The diagnosis is often realized when the disease is at an ad...
Eligibility Criteria
Inclusion
- Age ≥ 18 years at the day of consenting to the study
- Patient with a potential pancreatic adenocarcinoma whatever the TNM/UICC stage
- Systematic treatment not initiated
- Signed and dated informed consent document.
Exclusion
- Pregnant or breastfeeding woman
- Geographical, social or psychiatric reason preventing the patient from completing the study follow-up
Key Trial Info
Start Date :
May 22 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03472716
Start Date
May 22 2018
End Date
September 1 2023
Last Update
December 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Léon Bérard
Lyon, France, 69008